Nath Bio-GenesQ3 FY24Agricultural Food & other Products

Nath Bio-Genes

Q3 FY24 Earnings Call Analysis

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

Capex

0 of 5 growth signals are positive — mixed outlook.

Revenue guidance

Category 3

→Cotton sales expected to grow 15%-20% annually.
→Paddy sales projected to increase 10%-15%.
→Vegetable segment anticipated to grow 20%-25%.
→Plant nutrient supplements forecasted to expand rapidly with 25%-30% growth, contributing about 10% of current revenue and targeted to grow to 30%.
→Diversified product portfolio including maize, bajra, mustard, cotton, paddy, vegetables, and supplements supports balanced growth.
→Overall company growth targeted conservatively at 15%+, with potential upside if crop segments perform well.
→Uzbekistan JV expected to scale seed production post initial trial success, potentially doubling production by next year.
→Philippines export market viewed as supplementary "cherry on the cake," with uncertain but potential upside.
→Revenue goal of crossing 500 crores targeted within 2-3 years, indicating steady top-line expansion driven by current and new products.

Category 3

→The company targets a consistent sales growth of around 15% plus annually, with optimism for even 20-25% in some segments like vegetables and supplements.
→Cotton expected to grow 15-20%, paddy 10-15%, vegetables 20-25%, supplements 25-30%, contributing to overall growth.
→Gross profit margin maintained around 51-53%, with focus on product mix to sustain margins despite volume fluctuations.
→PAT growth expected in the range of 15-20%, supported by both existing and new product portfolios, including potential growth from Uzbekistan and Philippines markets.
→Management is conservative, expecting 15%+ growth but open to higher if achieved.
→EBITDA for H1 FY25 was ₹42.18 crores, profit after tax was ₹36.78 crores, reflecting steady profitability.
→No significant CAPEX planned; focus on optimizing working capital and leveraging vendor processing keeps costs controlled, supporting margins and profits.
→Expansion and diversification across crops and supplements expected to drive steady operating earnings growth.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Nath Bio-Genes and 1,400+ other companies.

→No current plans for CAPEX expenditure on plant and machinery, implying no immediate major funding needs (Page 20).
→The company has maintained nearly zero long-term debt for about 5-7 years and pays interest only on working capital (Pages 15, 17).
→Working capital is well managed and funded through advance bookings and bankers without raising new bank debt for nearly three years (Page 17).
→No term loans exist currently; any short-term funds are raised via short-duration NCDs and customer deposits (Page 15).
→No mention of any ongoing or planned equity fundraising during the call.
→The focus appears on organic growth and operational stability with no talk of inorganic growth or fundraising until crossing a revenue threshold of 500 crores (Page 9).
→Overall, no plans for new fundraising through debt or equity were indicated in the discussion.

→Nath Bio-Genes does not maintain a traditional advance order book like manufacturing industries.
→Instead, the company operates on an advanced booking basis through advance sales.
→Last year, advance bookings amounted to approximately ₹70-80 crores for the next year.
→There is no concept of formal advance orders as seed sales depend on seasonal demand and advance bookings.
→The company emphasizes working capital funded by advance bookings and bank facilities without increasing bank debt for about three years.
→No specific pending or current orderbook figures are mentioned.

→No CAPEX (capital expenditure) on plant and machinery is planned for this year or next year.
→The company relies on vendors for processing rather than investing in own plant and machinery, leading to low CAPEX, saving on depreciation, maintenance, and breakage costs.
→Over the past 5-7 years, there has been hardly any CAPEX recorded in the balance sheets.
→Strategic growth plans focus on organic growth with continued emphasis on diversifying portfolios (cotton, paddy, vegetables, plant nutrient supplements).
→The company is exploring opportunities in Uzbekistan with ongoing investment (about US$7-8 lakh so far) and hopes to scale based on performance by early next year.
→Expansion in exports, such as in the Philippines, is considered a potential growth avenue but not a core dependency.
→No inorganic growth via JV currently; consideration may come after crossing ₹500 crore revenue mark.

How does Nath Bio-Genes rank vs peers in Agricultural Food & other Products?

Pro feature

1Nath Bio-Genes

Rev 3Mar 3

See full Agricultural Food & other Products sector rankings

Want more stocks like Nath Bio-Genes?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.